References
- JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
- AlvarezMRomanESantosESRaezLENew targets for non-small-cell lung cancer therapyExpert Rev Anticancer Ther20077101423143717944567
- HilesIDOtsuMVoliniaSPhosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunitCell19927034194291322797
- Catalogue of Somatic Mutation in Cancer.[homepage on the Internet]EnglandSanger Institute [updated 2012 Dec 06]. Available from: http://www.cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIK3CAAccessed March 29, 2013
- OkudelaKSuzukiMKageyamaSPIK3CA mutation and amplification in human lung cancerPathol Int20075710664667117803655
- AnSJChenZHSuJIdentification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking statusPLoS One201276e4010922768234
- ChaftJEArcilaMEPaikPKCoexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profilingMol Cancer Ther201211248549122135231
- BoardREThelwellNJRavettoPFMultiplexed assays for detection of mutations in PIK3CAClin Chem200854475776018375489
- SpoerkeJMO’BrienCHuwLPhosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical modelsClin Cancer Res201218246771678323136191
- LuHYSuDPanXDJiangHMaSLMutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancerOncol Lett20123241542022740923
- SamuelsYEricsonKOncogenic PI3K and its role in cancerCurr Opin Oncol2006181778216357568
- ZhaoLVogtPKClass I PI3K in oncogenic cellular transformationOncogene200827415486549618794883
- KangSBaderAGVogtPKPhosphatidylinositol 3-kinase mutations identified in human cancer are oncogenicProc Natl Acad Sci USA2005102380280715647370
- EngelmanJAChenLTanXEffective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNat Med200814121351135619029981
- YamaguchiHYoshidaSMuroiEPhosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formationJ Cell Biol201119371275128821708979
- BabaYNoshoKShimaKPhosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancersCancer201117771399140821425139
- LiaoXLochheadPNishiharaRAspirin use, tumor PIK3CA mutation, and colorectal-cancer survivalN Engl J Med2012367171596160623094721
- OginoSNoshoKKirknerGJPIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancerJ Clin Oncol20092791477148419237633
- MangoneFRBobrovnitchaiaIGSalaorniSManuliENagaiMAPIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patientsClinics (Sao Paulo)201267111285129023184205
- LiaoXMorikawaTLochheadPPrognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature reviewClin Cancer Res20121882257226822357840
- Fariña SarasquetaAZeestratenECvan WezelTPIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosisCell Oncol (Dordr)201134652353121830111